| Abstract | Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. |
| Authors | Mouna Ben Djebara, Yulia Worbe, Michael Schüpbach, Andreas Hartmann
(Affiliation: Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.)
|
| Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 23
Issue 3
Pg. 438-40
(Feb 15 2008)
ISSN: 1531-8257 United States |
| PMID | 18067182
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
| Copyright | 2007 Movement Disorder Society |
| Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- aripiprazole
|
| Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- Humans
- Male
- Piperazines
(therapeutic use)
- Quinolones
(therapeutic use)
- Tourette Syndrome
(drug therapy)
- Treatment Outcome
|
